Company Analysis NeoGenomics, Inc.
1. Summary
Advantages
- The stock's return over the last year (29.72%) is higher than the sector average (-49.7%).
Disadvantages
- Price (15.8 $) is higher than fair price (11.89 $)
- Dividends (0%) are below the sector average (0.5496%).
- Current debt level 32.35% has increased over 5 years from 22.24%.
- The company's current efficiency (ROE=-9.34%) is lower than the sector average (ROE=9.61%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| NeoGenomics, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 13.3% | 2.5% | 1.3% |
| 90 days | 6.5% | -35.8% | 13.1% |
| 1 year | 29.7% | -49.7% | 37.2% |
NEO vs Sector: NeoGenomics, Inc. has outperformed the "Healthcare" sector by 79.42% over the past year.
NEO vs Market: NeoGenomics, Inc. has significantly underperformed the market by -7.49% over the past year.
Stable price: NEO is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: NEO with weekly volatility of 0.5716% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (15.8 $) is higher than the fair price (11.89 $).
Price is higher than fair: The current price (15.8 $) is 24.7% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (46.4) is lower than that of the sector as a whole (48.77).
P/E vs Market: The company's P/E (46.4) is lower than that of the market as a whole (48.12).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (2.76) is lower than that of the sector as a whole (4.82).
P/BV vs Market: The company's P/BV (2.76) is lower than that of the market as a whole (3.1).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (4.4) is lower than that of the sector as a whole (33.76).
P/S vs Market: The company's P/S indicator (4.4) is lower than that of the market as a whole (10.15).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-440.38) is lower than that of the sector as a whole (-22.12).
EV/Ebitda vs Market: The company's EV/Ebitda (-440.38) is lower than that of the market as a whole (18.05).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -239.92% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-239.92%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-9.16%).
5.4. ROE
ROE vs Sector: The company's ROE (-9.34%) is lower than that of the sector as a whole (9.61%).
ROE vs Market: The company's ROE (-9.34%) is lower than that of the market as a whole (10.88%).
5.5. ROA
ROA vs Sector: The company's ROA (-5.23%) is lower than that of the sector as a whole (0.3359%).
ROA vs Market: The company's ROA (-5.23%) is lower than that of the market as a whole (6.5%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-2.29%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (-2.29%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5496%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 15.08.2024 | ALICIA OLIVO Officer |
Purchase | 15.82 | 16 453 | 1 040 |
| 11.05.2024 | Harris Melody Chf Ops Off, Pres, Informatics |
Purchase | 15.4 | 108 847 | 7 068 |
| 11.05.2024 | Sherman Jeffrey Scott Chief Financial Officer |
Purchase | 15.4 | 400 554 | 26 010 |
| 11.05.2024 | Stone Warren Chief Commerical Officer |
Purchase | 15.4 | 296 050 | 19 224 |
| 11.05.2024 | Olivo Alicia C General Counsel |
Purchase | 15.4 | 200 262 | 13 004 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
